Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIITAL: EB-101 for RDEB
NCT04227106Phase 3Completed
- Sponsor
- Abeona Therapeutics Inc.
- Start
- Jan 2020
- Primary completion
- Oct 2022
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of prademagene zamikeracel in Recessive Dystrophic Epidermolysis Bullosa (RDEB) (2 arms), sponsored by Abeona Therapeutics Inc. Primary endpoints: Proportion of RDEB wound sites with >= 50% healing at 24 weeks and Pain reduction associated with wound dressing change at 24 weeks. Started Jan 2020; status: completed.
02
Drugs
prademagene zamikeracel
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT04227106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04227106.